A Policy Analysis on the Proactive Prevention of Chronic Disease: Learnings from the Initial Implementation of Integrated Measurement for Early Detection (MIDO)
Publish Year: 1396
نوع سند: مقاله ژورنالی
زبان: English
View: 8
This Paper With 6 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_HPM-6-6_006
تاریخ نمایه سازی: 18 مرداد 1403
Abstract:
Mexico, like many low- and middle-income countries (LMICs), faces an epidemic of chronic non-communicable diseases (NCDs), specifically diabetes, hypertension, obesity, and lipid disorders. Many people with these NCDs may not be aware that they have a disease, pointing to the need for broader screening programs. The traditional prevention policy in Mexico was based on screening with a paper-based risk factor questionnaire. However, this was used to screen patients already seeking healthcare services at facilities, and screening goals were set as a function of the number of questionnaires applied, not number of individuals screened. Due to this, Fundación Carlos Slim developed Medición Integrada para la Detección Oportuna (MIDOTM), or Integrated Measurement for Early Detection, an NCD screening and proactive prevention policy. This document is a policy analysis based on early learnings from the initial implementation of MIDO in eight primary healthcare centers in two central Mexican states. MIDO was found to expand screening programs beyond clinic walls, systematize community screening strategies, emphasize the detection of pre-disease phases, incorporate lifestyle counseling, and propose screening goals based on population targets. In collaboration with the Mexican Ministry of Health, MIDO has successfully screened over ۵۰۰ ۰۰۰ individuals—about ۴۰% of whom would not have been screened under previous policies. Of these more than ۵۰۰ ۰۰۰ screened individuals, ۱۳.۴% had pre-diabetes (fasting glucose between ۱۰۰ and ۱۲۵ mg/dL), and ۵.۸% had undiagnosed diabetes (defined as fasting glucose above ۱۲۶ mg/dL or random glucose above ۲۰۰ mg/dL). However, there is still room for improvement in linking positive results from screening with disease confirmation and with patient incorporation into disease management. The experience of implementing MIDO in Mexico suggests that primary and secondary prevention programs in other parts of the world should consider the need for population-based screening targets, a greater focus on pre-disease stages, and the streamlining of the transition between screening, confirmation of diagnosis, and incorporation of patients into the healthcare system.
Keywords:
Authors
Roberto Tapia-Conyer
Fundación Carlos Slim, Mexico City, Mexico
Rodrigo Saucedo-Martínez
Fundación Carlos Slim, Mexico City, Mexico
Ricardo Mújica-Rosales
Fundación Carlos Slim, Mexico City, Mexico
Héctor Gallardo-Rincón
Fundación Carlos Slim, Mexico City, Mexico
Evan Lee
Eli Lilly and Company, Lilly Global Health, Geneva, Switzerland
Craig Waugh
Lilly NCD Partnership, Indianapolis, IN, USA
Lucía Guajardo
Lilly NCD Partnership, Mexico City, Mexico
Braulio Torres-Beltrán
C۲۳۰ Consultores, Mexico City, Mexico
Úrsula Quijano-González
C۲۳۰ Consultores, Mexico City, Mexico
Mauricio López-Mendez
C۲۳۰ Consultores, Mexico City, Mexico
Elena Rose Atkinson
C۲۳۰ Consultores, Mexico City, Mexico
مراجع و منابع این Paper:
لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :